<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942926</url>
  </required_header>
  <id_info>
    <org_study_id>PB1</org_study_id>
    <nct_id>NCT03942926</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Sirolimus for Plastic Bronchitis</brief_title>
  <official_title>The Efficacy and Safety of Sirolimus for Plastic Bronchitisï¼ša Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North-China Pharmaceutical Company, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no confirmed drug therapy for plastic bronchitis. The study wish to test the
      effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic
      bronchitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plastic bronchitis is a rare respiratory disorder characterized by formation of gelatinous or
      rigid cast of bronchial tree. Confirmed drug therapy for plastic bronchitis is lacking.
      Recently, part of plastic bronchitis has been found to have dysfunction of lymphatic
      circulation in the lung. Pulmonary lymphatic perfusion syndrome (PLPS) is regarded as a major
      mechanism of lymphatic plastic bronchitis. Sirolimus (rapamycin) has not been studied in
      plastic bronchitis, however, it has been shown effective in several lymphatic disorders, such
      as lymphangioleiomyomatosis, generalized lymphatic anomaly (GLA) including lymphangiomatosis,
      etc. We wish to test the effectiveness of sirolimus in lymphatic plastic bronchitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2019</start_date>
  <completion_date type="Anticipated">May 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ten lymphatic bronchitis patients are planned to be recruited for the study. Sirolimus will be administered for 6 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of pulmonary lymphatic perfusion distribution</measure>
    <time_frame>6 months</time_frame>
    <description>quantitatively measured with 68Ga-NEB positron emission tomography (PET) at baseline and the end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of coughing score</measure>
    <time_frame>6 months</time_frame>
    <description>measured by coughing VAS score (0-10) at baseline, 3 months and the end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of pulmonary function (FEV1, FVC)</measure>
    <time_frame>6 months</time_frame>
    <description>measured by spirometry at baseline, 3 months and the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of six minutes walking distance</measure>
    <time_frame>6 months</time_frame>
    <description>measured by six minutes walking test at baseline, 3 months and the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of health-related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>measure by St George Respiratory Questionnaire at baseline, 3 months and the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of breathlessness score</measure>
    <time_frame>6 months</time_frame>
    <description>measured by Borg scale (0-10) at baseline, 3 months and the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) was used to collect adverse effects at baseline and through study completion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Plastic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in sirolimus group will receive sirolimus for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Patients will receive sirolimus for 6 months.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  plastic bronchitis

          -  pulmonary lymphatic perfusion syndrome demonstrated on 68Ga-NEB positron emission
             tomography (PET)

        Exclusion Criteria:

          -  Pregnancy and breastfeeding

          -  Severe cardiovascular, hepatic and renal dysfunction

          -  allergy to sirolimus or 68Ga-NEB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai-Feng Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kai-Feng Xu</last_name>
    <phone>010-69155039</phone>
    <email>xukf@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Feng Xu, M.D.</last_name>
      <phone>86-10-69155039</phone>
      <email>xukf@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xinlun Tian, M.D.</last_name>
      <phone>86-10-69155039</phone>
      <email>xinlun_t@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kai-Feng Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plastic bronchitis</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The protocol and clinical study report will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be shared between time of completion of the study and time of publication of the study.</ipd_time_frame>
    <ipd_access_criteria>contact principle investigator Dr Kai-Feng Xu via xukf@pumch.cn</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

